Mesoblast Ltd (MESO) - Total Assets
Based on the latest financial reports, Mesoblast Ltd (MESO) holds total assets worth $773.08 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mesoblast Ltd - Total Assets Trend (2005–2026)
This chart illustrates how Mesoblast Ltd's total assets have evolved over time, based on quarterly financial data. Also see MESO company net worth for the company's overall valuation and market capitalisation.
Mesoblast Ltd - Asset Composition Analysis
Current Asset Composition (June 2026)
Mesoblast Ltd's total assets of $773.08 Million consist of 25.6% current assets and 74.5% non-current assets. Review MESO total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.1% |
| Accounts Receivable | $57.66 Million | 7.5% |
| Inventory | $28.11 Million | 3.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $431.92 Million | 55.9% |
| Goodwill | $134.45 Million | 17.4% |
Asset Composition Trend (2005–2026)
This chart illustrates how Mesoblast Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Mesoblast Ltd stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mesoblast Ltd's current assets represent 25.6% of total assets in 2026, a decrease from 71.4% in 2005.
- Cash Position: Cash and equivalents constituted 6.1% of total assets in 2026, down from 70.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 3.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 55.9% of total assets.
Mesoblast Ltd Competitors by Total Assets
Key competitors of Mesoblast Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Mesoblast Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.43 | 1.99 | 1.36 |
| Quick Ratio | 2.09 | 1.77 | 1.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $116.38 Million | $101.72 Million | $33.32 Million |
Mesoblast Ltd - Advanced Valuation Insights
This section examines the relationship between Mesoblast Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.69 |
| Latest Market Cap to Assets Ratio | 2.48 |
| Asset Growth Rate (YoY) | -1.5% |
| Total Assets | $773.08 Million |
| Market Capitalization | $1.91 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Mesoblast Ltd's assets at a significant premium (2.48x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Mesoblast Ltd's assets decreased by 1.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Mesoblast Ltd (2005–2026)
The table below shows the annual total assets of Mesoblast Ltd from 2005 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | $773.08 Million | -1.48% |
| 2025-06-30 | $784.68 Million | +17.27% |
| 2024-06-30 | $669.15 Million | -0.04% |
| 2023-06-30 | $669.41 Million | +1.10% |
| 2022-06-30 | $662.14 Million | -11.09% |
| 2021-06-30 | $744.72 Million | +1.52% |
| 2020-06-30 | $733.60 Million | +12.50% |
| 2019-06-30 | $652.12 Million | -5.82% |
| 2018-06-30 | $692.44 Million | +5.61% |
| 2017-06-30 | $655.69 Million | -4.14% |
| 2016-06-30 | $684.02 Million | -32.80% |
| 2015-06-30 | $1.02 Billion | +13.19% |
| 2014-06-30 | $899.31 Million | +1.77% |
| 2013-06-30 | $883.71 Million | +22.66% |
| 2012-06-30 | $720.46 Million | -5.61% |
| 2011-06-30 | $763.25 Million | +1831.56% |
| 2010-06-30 | $39.51 Million | +46.49% |
| 2009-06-30 | $26.98 Million | -2.93% |
| 2008-06-30 | $27.79 Million | +30.84% |
| 2007-06-30 | $21.24 Million | +29.62% |
| 2006-06-30 | $16.38 Million | -23.67% |
| 2005-06-30 | $21.47 Million | -- |
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid … Read more